Article Text

Download PDFPDF
Peanut allergy: progress at last

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The publication of the STOP II trial from Cambridge in The Lancet produced significant mass media interest (Anagnostou K and colleagues. 2014–6). It was billed, with some justification, as having proved the first effective treatment for peanut allergy in children. Using oral immunotherapy (OIT) to bring about desensitisation is not new, but so far trials have been less successful in children than in adults, and peanut allergy has proved particularly difficult. The researchers studied 100 children age 7 to 16 from their specialist clinic at Addenbrooke's and the wider community. Each had a …

View Full Text


  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.